Associated Papers
Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective study.
Zhou H et al.
Discover Oncology, 2024
38847966 (PubMed )
Supplement: 12672_2024_1074_MOESM2_ESM.xlsx › Sheet1
Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity.
Shah SM et al.
Cancer Research Communications, 2024
38282550 (PubMed )
Supplement: crc-23-0312-s02.xlsx › Fig3B_EC_data
Resistance to TRK inhibition mediated by convergent MAPK pathway activation.
Cocco E et al.
Nature Medicine, 2019
31406350 (PubMed )
Supplement: NIHMS1533563-supplement-1.xlsx › Patient_6
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Chalmers ZR et al.
Genome Medicine, 2017
28420421 (PubMed )
Supplement: 13073_2017_424_MOESM7_ESM.xlsx › Sheet1
Select a paper to view details